Lung cancer study aims to uncover secrets of metastasis
NCT ID NCT07325864
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at genetic differences between the original lung cancer tumor and where it has spread in the body. Researchers will analyze DNA from stored tumor samples of 25 adults with non-small cell lung cancer. The goal is to better understand how lung cancer spreads, which could help develop future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why lung cancer spreads and point toward new targets for future treatments.
- What could go wrong
- This is a small, early observational study with no direct treatment. It may not lead to any immediate clinical benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient diagnosed with NSCLC
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients aged ≥18 years fit enough to tolerate the surgical operation; * the operative risk is considered low based on respiratory reserve and cardiac assessment; * the patient has clearly expressed willingness to adhere; * availability of pathological material for tumor DNA extraction and NGS execution. Exclusion Criteria: * Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study. * Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation. * Recent or ongoing severe or clinically significant infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer (diagnosis) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Istituto Europeo di Oncologia
RECRUITINGMilan, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI tailor recovery instructions after lung cancer surgery?
- Can a new radiation machine cut breath holds for cancer patients?
- Software aims to steer bronchoscopes more precisely in lung cancer checks
- Can a new targeted drug shrink lung tumors?
- Gentle exercise may revive energy in lung cancer patients
- Can a targeted drug delivery system shrink lung tumors?